

## CLAIMS

1. A method for the treatment of a hemangioma in a subject, the method comprising at least the step of locally administering an ACEi to the hemangioma.
2. A method as claimed in claim 1, wherein the method further comprises locally administering  
5 a beta-blocker to the hemangioma.
3. A method as claimed in any one of claims 1 to 3, wherein the method further comprises locally administering an ATIIR2 antagonist to the hemangioma.
4. A method for the treatment of a hemangioma in a subject, the method comprising at least the step of locally administering an ATIIR2 antagonist to the hemangioma.
- 10 5. A method as claimed in claim 4, wherein the method further comprises locally administering a beta-blocker to the hemangioma.
6. A method as claimed in claim 4, wherein the method further comprises locally administering an ACEi to the hemangioma.
7. A method as claimed in any one of claims 1 to 6, wherein the method comprises at least the  
15 step of locally administering an ACEi, a beta-blocker and an ATIIR2 antagonist to the hemangioma.
8. A method as claimed in any one of claims 1 to 6, wherein the method further comprises systemically administering an ACEi, a beta-blocker and/or an ATIIR2 antagonist to the subject.
- 20 9. A method as claimed in any one of claims 1 to 8, wherein two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists are administered.
10. A method as claimed in any one of claims 1 to 9, wherein local administration comprises topical administration and/or local injection.
11. A method as claimed in claim 9, wherein systemic administration comprises oral  
25 administration to the subject.
12. A method as claimed in claim 10, wherein where a beta-blocker and an ACEi are administered topically, the beta-blocker is administered in a lower amount relative to the amount of ACEi administered.
13. A method as claimed in any one of claims 1 to 3 or 6 to 8, wherein the ACEi is a prodrug.
- 30 14. A method as claimed in any one of claims 1 to 3, and 6 to 13, wherein an ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, Trandalopril, Quinapril, Benazepril, and Captopril.

15. A method as claimed in any one of claims 2, 3 and 5 to 14, wherein a beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.
16. A method as claimed in any one of claims 2, 3 and 5 to 15, wherein a beta-blocker is a non-selective beta-blocker.
17. A method as claimed in any one of claims 2, 3 and 5 to 16, wherein a beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S-Timolol.
18. A method as claimed in any one of claims 3 to 17, wherein an ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.
19. A method as claimed in any one of claims 1 to 18, wherein the method comprises locally administering: Cilazapril and R-propranolol; a) Ramipril or enalapril ortrandolapril and b) R-propranolol; a) Cilazapril and b) S-propranolol or racemic (R/S) propranolol; a) Ramipril or enalapril ortrandolapril and b) S-propranolol or racemic (R/S) propranolol; Cilazapril and timolol; a) Ramipril or enalapril ortrandolapril and b) timolol; a) L-159,686 or EMA401 and b) R-propranolol; a) L-159,686 or EMA401 and b) S-propranolol or racemic propranolol; a) L-159,686 or EMA401 and b) timolol; a) L-159,686 or EMA401 and b) cilazapril; or, a) L-159,686 or EMA401 and b) Ramipril or enalapril ortrandolapril.
20. A method as claimed in any one of claims 8 to 19, wherein the method comprises systemically administering: Cilazapril and R-propranolol; Enalapril and R-propranolol; a) Ramipril or enalapril ortrandolapril and b) R-propranolol; a) Cilazapril or ramipril or enalapril ortrandolapril and b) R-timolol; a) Cilazapril or enalapril and b) racemic (R/S) propranolol or S-propranolol; L-159,686 and R-propranolol; or, L-159,686 and racemic propranolol.
21. A method as claimed in any one of claims 1 to 20, wherein the method comprises administering: R-timolol and cilazapril; S-timolol and cilazapril; R/S-timolol and cilazapril; R-propranolol and cilazapril; S-propranolol and cilazapril; R/S-propranolol and cilazapril; L-159,686 and cilazapril; R-propranolol and L-159,686; S-propranolol and L-159,686; R/S-propranolol and L-159,686; L-159,686 and S-timolol; L-159,686 and R-timolol; EMA401 and S-timolol; EMA401 and R-timolol; EMA401 and cilazapril; EMA401 and R-propranolol; EMA401 and S-propranolol; or, EMA401 and R/S-propranolol.
22. A method as claimed in any one of claims 8 to 21, wherein the method comprises: locally administering Cilazapril and systemically administering propranolol (racemic (R/S) or R-); locally administering Ramipril or enalapril ortrandolapril and systemically administering propranolol (racemic (S/R) or R-); locally administering R-propranolol and systemically

- administering Cilazapril or captopril or enalapril; locally administering Timolol and systemically administering Cilazapril or captopril or enalapril; locally administering L-159,686 or EMA401 and systemically administering propranolol (racemic (S/R) or R-); locally administering L-159,686 or EMA401 and systemically administering cilazapril or captopril or enalapril; systemically administering L-159,686 or EMA401 and locally administering propranolol (racemic (S/R) or R-) or timolol; or, systemically administering L-159,686 or EMA401 and locally administering cilazapril or captopril or enalapril.
23. A method for the treatment of hemangioma in a subject, the method comprising at least the step of systemically administering two or more of a) an ACEi, b) a beta-blocker and, c) an ATIIIR2 antagonist to a subject.
24. A method as claimed in claim 23, wherein the method comprises administering: an ACEi and a beta-blocker; an ACEi and an ATIIIR2 antagonist; a beta-blocker and an ATIIIR2 antagonist; or an ACEi, a beta-blocker and an ATIIIR2 antagonist.
25. A method as claimed in claim 23 or 24, wherein two or more ACEi, two or more beta-blockers and/or two or more ATIIIR2 antagonists are administered.
26. A method as claimed in claim any one of claims 23 to 25, wherein an ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, Trandolapril, Quinapril, Benazepril, and Captopril.
27. A method as claimed in any one of claims 23 to 25, wherein a beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.
28. A method as claimed in any one of claims 23 to 26, wherein a beta-blocker is a non-selective beta-blocker.
29. A method as claimed in any one of claims 23 to 27, wherein a beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S-Timolol.
30. A method as claimed in any one of claims 23 to 28, wherein an ATIIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.
31. A method as claimed in one of claims 23 to 29, wherein the method comprises administering: Cilazapril and R-propranolol; Enalapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril or ramipril or enalapril or trandolapril and b) R-timolol; a) Cilazapril or enalapril and b) racemic (R/S) propranolol or S-propranolol; L-159,686 and R-propranolol; or, L-159,686 and racemic (R/S) propranolol.

32. A method as claimed in any one of claims 1 to 31, wherein the hemangioma is infantile hemangioma.
33. A composition comprising: an ACEi and a beta-blocker; an ACEi and an ATIIR2 antagonist; a beta-blocker and an ATIIR2 antagonist; or, an ACEi, a beta-blocker, and an ATIIR2 antagonist; wherein the composition is suitable for local administration.
34. A composition as claimed in claim 20, wherein the composition is suitable for topical administration.
35. A composition as claimed in claim 20 or 21, wherein the composition comprises two or more ACEi, two or more beta-blockers and/or two or more ATIIR2 antagonists.
36. A composition as claimed in any one of claims 20 to 22, wherein the composition comprises a lower amount of beta-blocker relative to the amount of ACEi.
37. A composition as claimed in any one of claims 20 to 23, wherein the ACEi is a prodrug.
38. A composition as claimed in any one of claims 33 to 37, wherein an ACEi is chosen from the group consisting of: Cilazapril, Enalapril, Ramipril, trandolapril, Quinapril, Benazepril, and Captopril.
39. A composition as claimed in any one of claims 33 to 38, wherein a beta-blocker is substantially in the R-enantiomer form, or comprises a racemic mixture having at least a predominance of the R-enantiomer form.
40. A composition as claimed in any one of claims 33 to 39, wherein a beta-blocker is a non-selective beta-blocker.
41. A composition as claimed in any one of claims 33 to 40, wherein a beta-blocker is chosen from the group consisting of: R-Propranolol; R/S Propranolol; R-Timolol; R/S Timolol; and, S-Timolol.
42. A composition as claimed in any one of claims 33 to 41, wherein an ATIIR2 antagonist is chosen from the group consisting of: L-159,686; and, EMA401.
43. A composition as claimed in any one of claims 33 to 42, wherein the composition comprises: Cilazapril and R-propranolol; a) Ramipril or enalapril or trandolapril and b) R-propranolol; a) Cilazapril and b) S-propranolol or racemic (R/S) propranolol; a) Ramipril or enalapril or trandolapril and b) S-propranolol or racemic (R/S) propranolol; Cilazapril and timolol; a) Ramipril or enalapril or trandolapril and b) timolol; a) L-159,686 or EMA401 and b) R-propranolol; a) L-159,686 or EMA401 and b) S-propranolol or racemic propranolol; a) L-159,686 or EMA401 and b) timolol; a) L-159,686 or EMA401 and b) cilazapril; or, a) L-159,686 or EMA401 and b) Ramipril or enalapril or trandolapril.

44. A composition as claimed in any one of claims 33 to 43, wherein the composition comprises:  
R-timolol and cilazapril; S-timolol and cilazapril; R/S-timolol and cilazapril; R-propranolol and  
cilazapril; S-propranolol and cilazapril; R/S-propranolol and cilazapril; L-159,686 and  
cilazapril; R-propranolol and L-159,686; S-propranolol and L-159,686; R/S-propranolol and L-  
5 159,686; L-159,686 and S-timolol; L-159,686 and R-timolol; EMA401 and S-timolol; EMA401  
and R-timolol; EMA401 and cilazapril; EMA401 and R-propranolol; EMA401 and S-  
propranolol; or, EMA401 and R/S-propranolol.
45. A method as claimed in any one of claims 1 to 32, wherein the method comprises  
administering: a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-  
10 selective beta-blocker and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in  
prodrug form.
46. A composition as claimed in any one of claims 33 to 44, wherein the composition comprises:  
a) an ACEi in prodrug form and a non-selective beta blocker; b) a non-selective beta-blocker  
and an ATIIR2 antagonist; or, an ATIIR2 antagonist and an ACEi in prodrug form.